Alyeska Investment Group
MYOV

Alyeska Investment Group’s Myovant Sciences Ltd. MYOV Stock Holding History

Alyeska Investment Group’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-100,404
Closed -$1.25M – 573
2016
Q4 		$1.25M Buy
+100,404
New +$1.16M 0.01% 417

Other funds holding MYOV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Alyeska Investment Group's MYOV Position: Q1 2017 in Review

Alyeska Investment Group sold out of Myovant Sciences Ltd. (MYOV) in Q1 2017, closing a stake of 100,404 shares — an estimated $1.25M sold.

Alyeska Investment Group first reported a position in MYOV in Q4 2016 and held it in 1 quarter. The position peaked at $1.25M in Q4 2016. 48 funds tracked by Wall St. Rank hold MYOV as of Q1 2017.

  • Alyeska Investment Group reported no remaining Myovant Sciences Ltd. position as of Q1 2017 after selling out during the quarter.
  • Alyeska Investment Group sold 100,404 Myovant Sciences Ltd. shares in Q1 2017, an estimated $1.25M.
  • Alyeska Investment Group first reported a position in Myovant Sciences Ltd. in Q4 2016 and held it in 1 quarter.
  • Alyeska Investment Group's Myovant Sciences Ltd. position peaked at $1.25M in Q4 2016.
  • 48 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2017.

Based on Alyeska Investment Group's 13F filing for Q1 2017, filed 15 May 2017.